| Literature DB >> 34437457 |
Agnieszka Tkaczyk1, Piotr Jedziniak1.
Abstract
Farm animals are frequently exposed to mycotoxins, which have many adverse effects on their health and become a significant food safety issue. Pigs are highly exposed and particularly susceptible to mycotoxins, which can cause many adverse effects. For the above reasons, an appropriate diagnostic tool is needed to monitor pig' exposure to mycotoxins. The most popular tool is feed analysis, which has some disadvantages, e.g., it does not include individual exposure. In recent years, the determination of biomarkers as a method to assess the exposure to mycotoxins by using concentrations of the parent compounds and/or metabolites in biological matrices is becoming more and more popular. This review provides a comprehensive overview of reported in vivo mycotoxin absorption, distribution, metabolism and excretion (ADME) and toxicokinetic studies on pigs. Biomarkers of exposure for aflatoxins, deoxynivalenol, ochratoxin A, fumonisins, T-2 toxin and zearalenone are described to select the most promising compound for analysis of porcine plasma, urine and faeces. Biomarkers occur in biological matrices at trace levels, so a very sensitive technique-tandem mass spectrometry-is commonly used for multiple biomarkers quantification. However, the sample preparation for multi-mycotoxin methods remains a challenge. Therefore, a summary of different biological samples preparation strategies is included in that paper.Entities:
Keywords: multi-mycotoxin LC-MS/MS method; mycotoxin biomarkers; pig health
Mesh:
Substances:
Year: 2021 PMID: 34437457 PMCID: PMC8402396 DOI: 10.3390/toxins13080586
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
NOAEL (no-observed-adverse-effect level) and LOAEL (lowest-observed-adverse-effect level) levels of selected mycotoxins recommended by EFSA.
| Mycotoxin | Pig Type | Adverse Effect | LOAEL | NOAEL | Ref. |
|---|---|---|---|---|---|
| DON | - | vomiting | 2.8 mg/kg feed | 0.7–12 mg/kg feed | [ |
| reduced feed intake and weight gain | 0.35 mg/kg feed | 0.7 mg/kg feed | |||
| FB1 | - | lung lesions | 0.4 mg/kg b.w./day | - | [ |
| increased serum Sa:So (sphinganine:sphingosine) ratios | 5 mg /kg feed | - | |||
| OTA | - | progressive nephropathy | 1 mg/kg feed | - | [ |
| effects on renal (diagnostic) enzyme levels and kidney function | 0.2 mg/kg feed | - | |||
| T-2 | - | immunological or haematological effects | 0.2 mg/kg feed | - | [ |
| ZEN | female prepubertal piglets | oestrogenic effects such as increased uterus weight and reddened and swollen vulva | 17.6 µg/kg b.w./day | 10.4 µg/kg b.w./day | [ |
| sexually mature female pigs | prolonged cycling | 200 µg/kg b.w./day | 40 µg/kg b.w./day |
DON—deoxynivalenol, FB1—fumonisin B1, OTA—ochratoxin A, T-2—T-2 toxin, ZEN—zearalenone.
Summary of recent (after year 2000) ZEN dose-respond studies in pigs.
| ZEN | Dose | Feed Type | Matrix 1 | Biomarker | Biomarker Concentration (ng/mL) | Matrix 2 | Biomarker | Biomarker Concentration (ng/mL) | Experiment Time | Number and Type of Pig | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | naturally contaminated wheat | urine | ZEN | 10.4 | serum | - | - | 35 days | 12–180 days old gilts | [ |
| 2 | 88 | 16.7 | |||||||||
| 3 | 235 | 15.4 | |||||||||
| 4 | 358 | 43.1 | |||||||||
| 1 | 10 | naturally | urine | ZEN | 2.7 ** | - | - | - | 37 days | 100 female piglets | [ |
| 2 | 60 | 34.8 | |||||||||
| 3 | 150 | 31.5 | |||||||||
| 4 | 220 | 64.1 | |||||||||
| 1 | 350 | naturally | urine | ZEN | - | - | - | - | 28 days | 24 castrated male pigs | [ |
| 2 | 720 | ||||||||||
| 3 | 1680 | ||||||||||
| 4 | 2360 | ||||||||||
| 1 | 10 | contaminated maise | urine | ZEN | 3.4 * (0.5–11.4) | serum | ZEN | 0 | 29 days | 125 female weaned piglets | [ |
| 2 | 50 | 25.9 (1.0–82.0) | 0–0.1 | ||||||||
| 3 | 80 | 51.7 (1.1–122) | 0–0.2 | ||||||||
| 4 | 170 | 79 (9.5–237) | 0–0.3 | ||||||||
| 5 | 290 | 136 (7.7–327) | 0–0.5 | ||||||||
| 1 | 6.04 | feed boluses fortified with pure cultures | urine | ZEN | 11.63 ± 7.52 | - | - | - | 3 days | 16 weaned piglets | [ |
| 2 | 17.23 | 23.06 ± 11.42 | |||||||||
| 3 | 21.13 | 15.76 ± 9.62 | |||||||||
| 4 | 50.26 | 17.08 ± 4.15 |
ZEN—zearalenone, ZEN-GlcAc—zearalenone glucuronide, α-ZEL—α-zearalenol, β-ZEL—β-zearalenol, ZAN—zearalanone, α-ZAL—α-zearalanol, β-ZAL—β-zearalanol, α-ZEL-GlcAc—α-zearalenol glucuronide. * median concentration, ()–range, ** mean concentration
Summary of recent (after year 2000) DON dose-respond studies in pigs.
| Feeding Group | Dose | Feed Type | Matrix 1 | Biomarker | Biomarker | Matrix 2 | Biomarker | Biomarker | Experiment Time | Number and Type of Pig | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 210 | contaminated wheat | urine | DON | 299 | serum | DONDOM-1 | 1 | 35 days | 12–180 days old gilts | [ |
| 2 | 3070 | 690 | 4.1 | ||||||||
| 3 | 6100 | 804 | 14.3 | ||||||||
| 4 | 9570 | 1572 | 21.6 | ||||||||
| 1 | 200 | contaminated maize | urine | DON | 56 | serum | DONDOM-1 | <LOQ | 37 days | 100 female piglets | [ |
| 2 | 800 | 162 | 1 (<LOQ-4) | ||||||||
| 3 | 1000 | 360 | 5 (<LOQ-12) | ||||||||
| 4 | 1900 | 246 | 6 (<LOQ-13) | ||||||||
| 5 | 3900 | 380 | 11 (6–19) | ||||||||
| 1 | 1110 | contaminated maize | urine | - | - | - | - | 28 days | 24 castrated male pigs | [ | |
| 2 | 2320 | ||||||||||
| 3 | 3700 | ||||||||||
| 4 | 5000 | ||||||||||
| 1 | 30 | contaminated maize | urine | DONDOM-1 | 68.3 (18.6–231) | serum | DONDOM-1 | 0.5 (0–1.4) | 29 days | 125 female weaned piglets | [ |
| 2 | 590 | 524 (50.8–1070) | 4.9 (2.7–7.9) | ||||||||
| 3 | 1270 | 1065 (96.2–2120) | 8.6 (4.6–15.9) | ||||||||
| 4 | 2010 | 1850 (288–4050) | 15.2 (8.1–24.9) | ||||||||
| 5 | 4520 | 2680 (244–4990) | 24.4 (9.9–42.8) | ||||||||
| 1 | 63.58 | fortified feed boluses | urine | DONDOM-1 | 80.55 ± 28.96 | - | - | - | 3 days | 16 weaned piglets | [ |
| 2 | 181.51 | 125.06 ± 41.64 | |||||||||
| 3 | 214.36 | 305.94 ± 143.17 | |||||||||
| 4 | 509.53 | 218.18 ± 33.35 |
DON—deoxynivalenol, DOM-1—deepoxy-deoxynivalenol.
Figure 1Correlation of ingested mycotoxin dose compared to the relevant urinary biomarker(s) excreted in 24 h post-dose for each mycotoxin/biomarker couple from studies in pigs (data from Table 2) (a) ZEN/ZEN, (b) ZEN/α-ZEL.
Figure 2Correlation of ingested mycotoxin dose compared to the relevant urinary biomarker(s) for each mycotoxin/biomarker couple from studies in pigs (data from Table 3). (a) DON/DON, (b) DON/DOM-1.
Figure 3Correlation of ingested mycotoxin dose compared to the serum DON concentration—data from recent studies in pigs (Table 3).
Summary of recent (after year 2000) AFB1, OTA, FB1 and T-2 dose-respond studies in pigs.
| Mycotoxin | Feeding Group | Dose | Feed Type | Matrix 1 | Biomarker | Biomarker | Matrix 2 | Biomarker | Biomarker | Experiment Time | Number and Type of Pig | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AFB1 | 1 | 0.16 | feed boluses fortified with pure cultures | urine | AFM1 | 0.14 | - | 3 days | 16 weaned piglets | [ | ||
| 2 | 0.45 | 0.36 | ||||||||||
| 3 | 0.54 | 0.50 | ||||||||||
| 4 | 1.28 | 0.88 | ||||||||||
| 1 | 127 | pure crystal AFB1 dissolved in methanol (20 mL) and | urine | AFM1 | 12.6 | - | 18 days | 4 castrated | [ | |||
| 2 | 227 | 17.2 | ||||||||||
| 3 | 327 | 22.6 | ||||||||||
| OTA | 1 | 0.16 | feed boluses fortified with mycotoxins | urine | OTA | 0.12 | - | 3 days | 16 weaned piglets | [ | ||
| 2 | 0.46 | 0.65 | ||||||||||
| 3 | 0.56 | 0.52 | ||||||||||
| 4 | 1.32 | 0.36 | ||||||||||
| OTA | 1 | 50 | basal diet mixed with pure OTA standard solutions | plasma | OTA | 22.2 ± 2.6 | - | 15 days | 12 pigs | [ | ||
| 2 | 500 | 217.4 ± 25.1 | ||||||||||
| 1 | 25 | crystalline OTA | urine | OTA | 3.1–4.35 | - | 119 days | 24 pigs | [ | |||
| 1 | 800 | naturally contaminated feed | serum | OTA | 852–1582 | - | 180 days | 6 pigs | [ | |||
| 1 | 120 | naturally contaminated feed | plasma | OTA | 82.8 | 28 days | 48 piglets | [ | ||||
| 1 | 250 | OTA-fortified feed | urine | OTA | 16.1 | serum | OTA | 4.8 | 28 days | 10 pigs | [ | |
| 1 | 300 | pure OTA standard mixed with lactose and formulated as gelatine capsules | plasma | OTA | 6.4 | 30 days | 10 pigs | [ | ||||
| 1 | 114 | naturally contaminated feed | urine | OTA | 18.8 ± 6.4 | serum | OTA | 141 ± 47.9 | 28 days | 24 pigs | [ | |
| 2 | 226 | 36.5 ± 11.6 | 278 ± 106 | |||||||||
| FB1 | 1 | 3.71 | feed boluses fortified with pure cultures | urine | FB1 | 1.55 | - | 3 days | 16 weaned piglets | [ | ||
| 2 | 10.6 | 3.36 | ||||||||||
| 3 | 64.2 | 77.37 | ||||||||||
| 4 | 150 | 117.78 | ||||||||||
| 1 | 5 | aqueous stock solutions | urine | FB1 | - | faeces | FB1 | - | 96 h | male weaned piglets | [ | |
| 1 | 3.1 | culture material added to feed | urine | FB1 | 16.09 ± 21.94 | plasma | FB1 | 0.16 ± 0.04 | 28 days | 24 piglets | [ | |
| 2 | 6.1 | 24.08 ± 25.96 | 0.26 ± 0.06 | |||||||||
| 3 | 9.0 | 18.88 ± 4.41 | 0.42 ± 0.10 | |||||||||
| FB1
| 1 | 50 mg/animal | urine (13–17 day) | FB1 | 4.5 ± 3.9 mg | faeces | FB1FB2 | 28.2 ± 27.3 mg | 22 days | 6 cross-bred pigs (plasma) | [ | |
| 2 | 20 mg/animal | |||||||||||
| 3 | 5 | |||||||||||
| T-2 | 1 | 500 | aqueous stock solutions | urine | T-2 | 30.9 ± 2.1 | faeces | HT-2 | 104.6 ± 14.2 | 1 day | 7 cross-bred pigs | [ |
AFB1—aflatoxin B1, AFB2—aflatoxin B2, AFM1—aflatoxin M1, OTA—ochratoxin A, OTα—ochratoxin alpha. FB1—fumonisin B1, FB2—fumonisin B2, T-2—T-2 toxin, HT-2—HT-2 toxin.
The essential biomarkers (with adequate sampling time in brackets (when studied)) found in pig biological matrices in vivo studies with pigs (in bold are biomarkers found at the highest concentration).
| Mycotoxin/Matrix/Time | Urine | Faeces | Plasma |
|---|---|---|---|
| DON | DON (4–8 h) | DOM-1 (8–24 h) | DON-3-GlcAc (3–4 h) |
| ZEN | ZEN-GlcAc (12–24 h) ZEN * (12–24 h) | ZEN (12–24 h) | ZEN-GlcAc (0.25–3 h) |
| OTA | OTA | n.d. | OTA (72–120 h) |
| FB1/FB2 | FB1 (8–24 h) | FB1 (8–24 h) | FB1 (2 h) |
| AFB1 | AFM1 | n.d. | n.d. |
| T-2 | HT-2 (12–24 h) | HT-2 | T-2 (3 h) |
* analysis after enzymatic hydrolysis. DON—deoxynivalenol, DOM-1—deepoxy-deoxynivalenol, DON-GlcAc—deoxynivalenol glucuronide, ZEN—zearalenone, ZEN-GlcAc—zearalenone glucuronide, α-ZEL—α-zearalenol, β-ZEL—β-zearalenol, ZAN—zearalanone, α-ZAL—α-zearalanol, β-ZAL—β-zearalanol, OTA—ochratoxin A, OTα—ochratoxin alpha, FB1—fumonisin B1, FB2—fumonisin B2, AFB1—aflatoxin B1, AFB2—aflatoxin B2, AFM1—aflatoxin M1, T-2—T-2 toxin, HT-2—HT-2 toxin, T-2 triol—T-2 toxin triol.